Table 3.
Changes in 2D diameter and ADC values, initial diameter, response, and neoadjuvant chemotherapy regimens in all lesions. The top half of the table includes lesions with pathological complete response (pCR), and below are lesions without (non-pCR)
| 2D diameter size change from BS [%] | Mean ADC values [×10-3 mm2/s] | ||||||
|---|---|---|---|---|---|---|---|
| Patient number | NACT regimen | Response | Initial diameter at BS (cm) | 2nd-4th cycle | after 5th cycle | 2nd-4th cycle | after 5th cycle |
| 1 | TA | pCR | 2.34 | n/a | -100 | n/a | n/a |
| 2 | CA - T | pCR | 8.58 | -40 | n/a | 1.59 | 1.49 |
| 3 | CA - T | pCR | 3.09 | -43 | -64 | 1.37 | 0.91 |
| 4 | CA – T | pCR | 3.04 | -28 | -78 | 1.39 | 1.18 |
| 5 | TA, Tr | pCR | 4.42 | -100 | -100 | 1.24 | n/a |
| 6 | TA | pCR | 6.9 | -100 | -100 | 1.09 | 0.97 |
| 7 | T - CA | pCR | 4.83 | -73 | -100 | 0.92 | 0.95 |
| 8 | CA - T | non-pCR | 2.98 | -91 | -100 | 1.25 | n/a |
| 9 | CA - T, Tr | non-pCR | 6.85 | n/a | -32 | n/a | 0.87 |
| 10 | TA | non-pCR | 9.15 | -7 | -38 | 1.54 | 1.53 |
| 11 | TA | non-pCR | 2.63 | -22 | -100 | 1.44 | 2.08 |
| 12 | T - CA | non-pCR | 3.12 | -28 | -55 | 1.13 | 1.53 |
| 13 | CA - T | non-pCR | 10.28 | -28 | -28 | 1.89 | 1.67 |
| 14 | TA | non-pCR | 4.5 | -19 | -100 | 0.99 | 1.61 |
| 15 | CA - T | non-pCR | 6.35 | n/a | -34 | n/a | 1.04 |
| 16 | TA | non-pCR | 4.1 | -17 | -35 | 1.03 | 1.20 |
| 17 | TA, Tr | non-pCR | 10.64 | -48 | -64 | 1.22 | 1.51 |
| 18 | CA - T | non-pCR | 4.39 | n/a | -47 | n/a | 1.58 |
| 19 | CA - T, Tr | non-pCR | 6.84 | n/a | -100 | n/a | n/a |
| 20 | T - CA | non-pCR | 5.29 | -86 | -71 | 1.76 | 1.47 |
| 21 | CA - T | non-pCR | 10.11 | -3 | -100 | 1.13 | 2.03 |
| 22 | TA | non-pCR | 2.98 | -38 | -57 | 0.98 | 1.23 |
| 23 | TA | non-pCR | 9.88 | n/a | -100 | n/a | 1.38 |
| 24 | TA | non-pCR | 2.97 | n/a | -51 | 0.76 | 1.17 |
| 25 | CA - T | non-pCR | 6.51 | -100 | n/a | 1.07 | n/a |
| 26 | TA | non-pCR | 2.97 | -32 | n/a | 1.31 | n/a |
| 27 | TA | non-pCR | n/a | n/a | n/a | 0.89 | 0.87 |
| 28 | TA | non-pCR | 4.02 | -34 | -100 | 0.96 | 1.33 |
| 29 | TA | non-pCR | 4.82 | n/a | -29 | n/a | 1.15 |
| 30 | T - CA | non-pCR | 2.05 | -23 | -21 | 1.60 | 0.99 |
| 31 | TA | non-pCR | 2.36 | -46 | -100 | 0.97 | n/a |
| 32 | TA | non-pCR | 7.05 | -12 | -7 | 1.47 | 1.86 |
| 33 | CA - T | non-pCR | 5.38 | -18 | n/a | 1.27 | n/a |
| 34 | TA | non-pCR | 4.49 | n/a | -20 | n/a | 0.91 |
| 35 | TA | non-pCR | 7.58 | 1 | -9 | 1.12 | 1.43 |
| 36 | CA - T | non-pCR | 2.39 | 17 | 4 | 0.98 | 1.00 |
| 37 | CA - T | non-pCR | 8.88 | -23 | -33 | 1.10 | 1.54 |
| 38 | T, Tr | non-pCR | 2.4 | -25 | -28 | 1.00 | 1.01 |
| 39 | TA | non-pCR | 10.32 | -1 | n/a | 1.46 | n/a |
| 40 | TA, Tr | non-pCR | 3.52 | -20 | -28 | 1.51 | 1.27 |
| 41 | CA - T | non-pCR | 12.48 | 0 | -4 | 0.80 | 0.98 |
| 42 | CA - T | non-pCR | 6.55 | 33 | 64 | 1.38 | 1.41 |
Note: T taxane, A anthracycline, C cyclophosphamide, Tr traustuzumab, NACT neoadjuvant chemotherapy, n/a value missing